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Abstract
Background: During a viral infection, the intracellular RIG-I-like receptors (RLRs) sense viral RNA and signal through
the mitochondrial antiviral signaling adaptor MAVS (also known as IPS-1, Cardif and VISA) whose activation triggers
a rapid production of type I interferons (IFN) and of pro-inflammatory cytokines through the transcription factors
IRF3/IRF7 and NF-B, respectively. While MAVS is essential for this signaling and known to operate through the
scaffold protein NEMO and the protein kinase TBK1 that phosphorylates IRF3, its mechanism of action and
regulation remain unclear.
Results: We report here that RLR activation triggers MAVS ubiquitination on lysine 7 and 10 by the E3 ubiquitin
ligase TRIM25 and marks it for proteasomal degradation concomitantly with downstream signaling. Inhibition of
this MAVS degradation with a proteasome inhibitor does not affect NF-B signaling but it hampers IRF3 activation,
and NEMO and TBK1, two essential mediators in type I IFN production, are retained at the mitochondria.
Conclusions: These results suggest that MAVS functions as a recruitment platform that assembles a signaling
complex involving NEMO and TBK1, and that the proteasome-mediated MAVS degradation is required to release
the signaling complex into the cytosol, allowing IRF3 phosphorylation by TBK1.
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Background
Upon infection, viruses are rapidly recognized by the
innate immune system through germ line-encoded pat-
tern-recognition receptors (PRRs) [1]. Several classes of
PRR, including Toll-like receptors (TLRs) and RIG-I-like
receptors (RLRs), recognize viral components and directly
activate immune cells. The RLRs are comprised of RIG-I
and MDA-5 (melanoma differentiation-associated gene-5)
that are cytosolic helicases sensing viral RNA [2]. Impor-
tantly, RIG-I and MDA-5 contain two CARDs (Caspase
Activation and Recruitment Domains) [1,2]. The ATPase
activity of both helicases as a result of binding to their
ligands is required for conformational changes that lead to
the exposure of the CARDs otherwise masked by the
C-terminal regulatory domain. This conformational
change is required for a putative interaction with the
CARD domain of the mitochondrial adaptor MAVS (also
known as IPS-1, Cardif or VISA) [3-6]. MAVS then acti-
vates two cytosolic protein kinase complexes, one consist-
ing of the “noncanonical” IKK-related kinase TBK1
(TANK-binding kinase 1) or IKK-i/ε (inducible IB
kinase) associated with various adaptor proteins like
TANK (TRAF family member associated NF-Ba c t i v a t o r ) ,
NAP1 (NAK-associated protein 1) and NEMO (NF-B
Essential MOdulator), and the other comprising IKKa,
IKKb and NEMO [1]. The TBK1 complex leads to phos-
phorylation and dimerization of the transcription factors
IRF3 and IRF7, which translocate to the nucleus and bind
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resulting in the expression of type I IFN genes and a set of
IFN-inducible genes. The IKK complex activates NF-B,
subsequently promoting the expression of pro-inflamma-
tory cytokines [1].
Interestingly, it has been reported that MAVS must be
localized to mitochondria to exert its function [5], suggest-
ing that the mitochondrial environment is required for sig-
nal transduction following RLR activation. In agreement
with this hypothesis, we recently reported that mitochon-
drial dynamics regulate MAVS-mediated signaling [7].
Nevertheless, the regulation of MAVS in the RLR pathway
remains unclear.
Here, we report that RLR activation induces a selective
proteasomal degradation of the larger MAVS isoform,
subsequent to its ubiquitination on lysine 7 and 10 by the
E3 ubiquitin ligase TRIM25. Surprisingly, this MAVS
degradation seems to be required for the downstream sig-
naling leading to type I IFN production, since its inhibition
w i t hap r o t e a s o m ei n h i b i t o rprevents IRF3 activation.
Importantly, we observed that prevention of the selective
MAVS degradation leads to a retention at the mitochon-
dria of NEMO and TBK1. Thus, our results suggest that
MAVS acts as a recruitment platform for the assembly
and activation of a signaling complex, and that MAVS
degradation is likely required to release this signaling com-
plex into the cytosol for IRF3 phosphorylation and ensuing
type I IFN production.
Results
RLR activation promotes a selective degradation of the
larger MAVS isoform concomitantly with downstream
signaling
To gain insight into the function and regulation of
MAVS following RLR activation, we investigated the
kinetics of signaling downstream of RIG-I by infecting
HEK293T or HeLa cells with the Sendaï virus (SeV) H4
strain [8], a strain composed mostly of small, copy-back
defective interfering genomes and whose infection over-
produces short uncapped 5’-triphosphate RNAs that are
specific ligands for RIG-I [2]. Accordingly, RIG-I has
been reported to be essential for the production of type
I IFN in response to SeV [9]. As a control, a wild-type
(WT) SeV strain was used. Immunoblot analyses at dif-
ferent time points following infection of cells with these
SeV strains confirmed that, unlike SeV WT, SeV H4
activates the RLR pathway as observed by the phosphor-
ylation of both IRF3 and the NF-B inhibitor IBa
(Figure 1A). RLR activation led to type I IFN production
as assessed by the up-regulation of RIG-I in SeV
H4-infected cells (Figure 1A). Next, in assays where a
luciferase reporter was either under the control of the
IFN-b promoter or driven by three copies of an NF-B
enhancer, SeV H4 activated not only the IFN-b promo-
ter but also NF-B, in contrast to SeV WT (Figure 1B).
In different cell lines, including HEK293T, HeLa
(Figure 1A), A549, Huh7 or Jurkat cells (data not
shown), MAVS is expressed as two major isoforms, as
previously reported [5], and siRNAs raised against
MAVS knock down the expression of the different iso-
forms (Figure 1D). Interestingly, following SeV H4 but
not SeV WT infection, the larger isoform was degraded,
whereas the shorter isoform was not affected (Figure 1A).
Intriguingly, degradation of the larger MAVS isoform
was concomitant with the phosphorylation of both IRF3
and IBa, suggesting that this degradation could be con-
nected to downstream signaling. Similar degradation was
also observed in polyinosine-polycytidylic acid (poly(I:
C))-transfected HeLa cells (Figure 1C) (in that case, poly
(I:C) are sensed by MDA-5 [9]) or in Vesicular Stomatitis
Virus (VSV)-infected cells (data not shown). Specific
degradation of the larger MAVS isoform was also
remarked after lysis in a buffer containing Sodium Dode-
cyl Sulfate (SDS) (Additional file 1) ruling out the
hypothesis that the larger MAVS isoform moves into an
insoluble fraction following RLR activation.
To assess whether this specific MAVS degradation is not
a consequence of a feedback loop mediated by the produc-
tion of type I IFN, cells were either treated with IFN-a2o r
IFN-b, or treated after infection with a neutralizing anti-
body raised against IFNAR1, a chain of the IFN-a/b recep-
tor. Unlike RLR activation, we observed that stimulation of
cells with IFN did not promote MAVS degradation and
inhibition of IFNAR1 did not prevent the degradation as
well (Additional file 2) indicating that MAVS degradation
is not a consequence of the production of type I IFN.
MAVS degradation upon RLR activation is independent of
a specific protease
The finding that the larger MAVS isoform is selectively
degraded following RLR activation prompted us to investi-
gate the mechanism of this degradation. First, by RT-PCR,
we did not observe any differences in MAVS mRNAs in
infected cells in comparison to non-infected cells (data not
shown) suggesting a post-translational regulation of
MAVS. It has been reported that MAVS can be processed
and inactivated by a specific cleavage triggered by the hepa-
titis C virus serine protease NS3-4A or by cellular caspases
activated by various pro-apoptotic signals [4,10]. A degra-
dation of the larger MAVS isoform occurred following SeV
H4, but not WT, infection (Figure 1A), implying that
MAVS is not cleaved by a specific SeV protease. In addi-
tion, MAVS degradation occurred independently of
caspases, since it was not prevented by the broad spectrum
caspases inhibitor zVAD-fmk (Additional file 3A). By
contrast, MAVS cleavage, as well as PARP processing,
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Page 2 of 13were abrogated in cells undergoing apoptosis in the pre-
sence of the caspase inhibitor (Additional file 3A). The cas-
pase inhibitors zVAD-fmk and qVD-fmk had no effect on
activation of IFNb promoter or NF-B as assessed in luci-
ferase assays (Additional file 3B). Likewise, treatment with
Leupeptin and Pepstatin, which are inhibitors of trypsin-
like/some serine proteases and acid proteases, respectively,
did not hamper MAVS degradation and downstream sig-
naling (Additional files 3C, D).
RLR activation triggers MAVS ubiquitination and
degradation by the proteasome
Since protease inhibitors had no effect on MAVS degrada-
tion, we hypothesized that MAVS might be degraded by
the proteasome. It is believed that polyubiquitin chains
linked through lysine at position 48 of ubiquitin (Lys 48)
target protein substrates for degradation by the protea-
some, whereas polyubiquitin chains of alternative linkages
(such as Lys 63) carry out signaling functions independent
of proteolysis [11]. Analysis of MAVS in the mitochondrial
fraction from SeV H4-infected cells demonstrated that
MAVS is rapidly ubiquitinated during infection (Figure
2A), as previously described [12]. Importantly, treatment
with the proteasome inhibitor MG132 prevented degrada-
tion of the larger MAVS isoform (Figure 2B), signifying
that following RLR activation, the larger MAVS isoform is
ubiquitinated then selectively degraded by the proteasome.
Surprisingly, the proteasome inhibition not only impaired
MAVS degradation following RLR activation but also pre-
vented IRF3 phosphorylation (Figure 2C), its nuclear
translocation (Figure 2D) and ensuing type I IFN produc-
tion, as assessed by the lack of RIG-I expression (Figure
2C) or by luciferase assays (Figure 2E). Interestingly, pro-
teasome inhibition did not impair IBa phosphorylation
(Figure 2C), indicating that prevention of MAVS degrada-
tion has no impact on IKK activation. Nevertheless, as
expected, MG132 treatment inhibited NF-B activation
because IBa is degraded by the proteasome once
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Figure 1 The larger MAVS isoform is selectively degraded concomitantly with downstream signaling following RLR activation. (A)
HEK293T or HeLa cells were infected with SeV WT or H4, and at various times after infection RIG-I, MAVS, p-IRF3, IRF3, p-IBa and IBa were
analyzed in cell extracts by immunoblotting. Actin was used as a protein loading control. (B) HEK293T cells were transfected with either an IFN-b
promoter reporter or with NF-B reporter as well as with renilla luciferase as an internal control. Twenty hours after transfection, cells were
infected with SeV WT or SeV H4 or else left non-infected (-). Luciferase assay was performed 8 hr after infection and was normalized using renilla
luciferase activity. Data represent means ± SD (n = 3). (C) HeLa cells were transfected with HMW Poly(I:C) (1 μg/ml) for 9 hr and then, cell
extracts were analyzed by immunoblotting. * Probable non-specific protein bands. Values represent the ratio of the larger MAVS isoform band
normalized with respect to the loading control, analyzed with ImageJ software. (D) Control or MAVS siRNAs were transfected into HEK293T or
HeLa cells. Knockdown of MAVS was confirmed by immunoblotting 72 hr later.
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Page 3 of 13phosphorylated (Figures 2C, E) [11]. Finally, the use of lac-
tacystin, another proteasome inhibitor, also prevented acti-
vation of the IFN-b promoter (Figure 2E). Together, our
observations strongly suggest that the proteasome-
mediated degradation of MAVS is required for the signal
transduction that leads to IRF3 activation and ensuing
type I IFN production.
The E3 ubiquitin ligase TRIM25 targets MAVS for
ubiquitination and degradation
To identify an E3 ubiquitin ligase involved in the selec-
tive degradation of MAVS, cells were infected with SeV
H 4f o rf o u rh o u r s ,a n dt h ep u r i f i e dM A V Sc o m p l e x
after immunoprecipitation was analyzed by mass spec-
trometry. Four E3 ubiquitin ligases were identified by
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Figure 2 RLR activation induces proteasomal degradation of the larger MAVS isoform after its polyubiquitination. (A) HeLa cells were
infected with SeV H4 in the presence of MG132. At different times after infection, MAVS and its ubiquitination were analyzed in mitochondrial
extracts by immunoblotting with a short and a long exposure respectively. (B) HeLa cells were infected with SeV H4 in the presence or the
absence of MG132. Nine hours after infection, MAVS was analyzed in cell extracts by immunoblotting. (C) HEK293T cells were infected with SeV
H4 in the presence or the absence of MG132, then at various times after infection, RIG-I, MAVS, p-IRF3, IRF3, p-IBa and IBa were analyzed in
cell extracts by immunoblotting. (D) HeLa cells were infected or not with SeV H4 for 8 hr in the presence or the absence of MG132. Next,
nuclear translocation of IRF3 was assessed by immunofluorescence. (E) HEK293T cells were transfected with either an IFN-b promoter reporter or
with NF-B reporter as well as with renilla luciferase as an internal control. 24 hr after transfection, cells were infected with SeV WT or SeV H4 or
else left non-infected (-) and treated with different proteasome inhibitors. Luciferase assay was performed 8 hr after infection and was
normalized using renilla luciferase activity. Data represent means ± SD (n = 3).
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Page 4 of 13mass spectrometry, and among them TRIM25 drew our
attention (Figure 3A) because this E3 ubiquitin ligase
was already known to be involved in the RLR pathway.
Indeed, TRIM25 induces the Lys 63-linked ubiquitina-
tion of RIG-I to stabilize the interaction with MAVS
[13] but TRIM25 is also capable of promoting Lys 48-
linked ubiquitination and degradation of proteins
[14,15]. Interaction between MAVS and TRIM25 was
confirmed by co-immunoprecipitation of endogenous
MAVS, and the interaction was slightly enhanced after
SeV H4 infection (Figure 3B). Transfection of TRIM25
increased MAVS ubiquitination (Figure 3C) and pro-
moted specifically a modest but significant degradation
o ft h el a r g e rM A V Si s o f o r m( F i g u r e3 D ) .I ns h a r p
contrast, two other mitochondrial proteins anchored
into the outer membrane, namely Mfn1 and Bcl-2,
remained unaffected (Figure 3D). Importantly, TRIM25
catalyzed MAVS ubiquitination with WT ubiquitin and
ubiquitin-K48, but not with ubiquitin-K63 (Figure 3E).
Because only the larger MAVS isoform is degraded fol-
lowing RLR activation, we hypothesized that the lysine
residues that are targeted by TRIM25 to promote
MAVS ubiquitination are only present in the larger iso-
form. The shorter MAVS isoform is a truncated form
which lacks the N-terminus but retains the C-terminal
transmembrane domain (unpublished observation and
[16]). Sequence analysis revealed that two lysines (K7
and K10) are present in the larger isoform only. We,
B 
A 
MAELCPLAEELSCSICLEPFKEPVTTPCGHNFCGSCLNETWAVQGSPYLCPQCRA
VYQARPQLHKNTVLCNVVEQFLQADLAREPPADVWTPPARASAPSPNAQVACDHC
LKEAAVKTCLVCMASFCQEHLQPHFDSPAFQDHPLQPPVRDLLRRKCSQHNRLRE
FFCPEHSECICHICLVEHKTCSPASLSQASADLEATLRHKLTVMYSQINGASRAL
DDVRNRQQDVRMTANRKVEQLQQEYTEMKALLDASETTSTRKIKEEEKRVNSKFD
TIYQILLKKKSEIQTLKEEIEQSLTKRDEFEFLEKASKLRGISTKPVYIPEVELN
HKLIKGIHQSTIDLKNELKQCIGRLQEPTPSSGDPGEHDPASTHKSTRPVKKVSK
EEKKSKKPPPVPALPSKLPTFGAPEQLVDLKQAGLEAAAKATSSHPNSTSLKAKV
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Figure 3 The E3 ubiquitin ligase TRIM25 catalyzes Lys 48-linked ubiquitination of MAVS. (A) The sequence of TRIM25 and the matching
endogenous peptides (highlighted in yellow) were identified by mass spectrometry. (B) HEK293T cells were infected with SeV H4 in the
presence of MG132 for 6 hr. Next, endogenous MAVS was immunoprecipitated from cell extracts; the presence of MAVS and TRIM25 was
examined by immunoblotting. (C) HEK293T cells were transfected with TRIM25-V5 or control plasmid for 24 hr. Next, endogenous MAVS was
immunoprecipitated in denaturing conditions from cell extracts with specific antibody; the presence of MAVS and its ubiquitination was
examined by immunoblotting. (D) HEK293T cells were transfected with TRIM25-V5 or control plasmid, and 72 hr after transfection, Mfn1, MAVS,
V5 (TRIM25) and Bcl-2 were analyzed in cell extracts by immunoblotting. Values represent the ratio of the larger MAVS isoform band normalized
with respect to the loading control. (E) HEK293T cells were transfected with the indicated plasmids. Twenty-four hours after transfection,
immunoprecipitation and immunoblot analysis were performed with the indicated antibodies (upper panel). Expression of the proteins was
examined by immunoblots with the indicated antibodies (lower panel). (F) Experiment was performed as in E. Myc-MAVS
mut: Myc-MAVS
(K7R/K10R)
mutant.
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Page 5 of 13therefore, mutated K7 and K10 and investigated whether
the mutation affects TRIM25-mediated MAVS ubiquitina-
tion. While a single mutation (K7R or K10R) partially
reduces the ubiquitination profile of MAVS (data not
shown), MAVS ubiquitination was strongly inhibited
when a double mutation was realized (K7R/K10R) (Figure
3F). Accordingly, MAVS degradation was also prevented
(Figure 3F). Because of K7’s and K10’s close proximity, we
speculate that they likely compensate for each other.
Together, these data suggest that TRIM25 targets MAVS
at K7 and K10 for ubiquitination and degradation.
TRIM25 was described to act upstream of MAVS
through the ubiquitination of RIG-I but not of MDA-5
[13]. To circumvent this trouble, we transfected HMW
poly(I:C) into cells because this synthetic dsRNA analog
is sensed by MDA-5 but not by RIG-I [9] (Figure 4B)
and, thus, we noticed that transfection of TRIM25 aug-
ments activation of the IFNb promoter once cells are
stimulated (Figure 4A). In TRIM25 siRNA-transfected
cells or in TRIM25 -/- MEFs, we observed that IFNb
production was significantly impeded after activation
with poly(I:C), indicating that TRIM25 also regulates the
RLR pathway independently of RIG-I (Figures 4B, C).
Importantly, in TRIM25 -/- MEFs, IL-6 production was
similar as in WT MEFs following transfection with poly
(I:C) (Figure 4D), suggesting that TRIM25-mediated
degradative ubiquitination of MAVS does not regulate
NF-B-induced cytokine production but only type I IFN
synthesis (Figure 4C). Confirming this, immunoblot ana-
l y s e ss h o w e dt h a tt h ek n o c kd o w no fT R I M 2 5i n h i b i t s
the degradation of the larger MAVS isoform as well as
the ensuing phosphorylation of IRF3, but not of IBa
after activation (Figures 4E, F). Furthermore, MAVS ubi-
quitination was strongly inhibited in TRIM25 -/- MEFs
in comparison to WT MEFs after transfection with poly
(I:C) (Figure 4G). Collectively, our data demonstrate
that TRIM25 binds to MAVS and promotes its K48-
linked ubiquitination and proteasome-mediated degrada-
tion to allow IRF3 but not NF-B activation once RLRs
are stimulated. Interestingly, the knock down of
TRIM25 led to the appearance of a protein band above
the larger MAVS isoform after stimulation in human
c e l l s( F i g u r e4 E ) ,a n do u rr e s u l t si n d i c a t et h a ti tc o r r e -
sponds to a phosphorylated state (Additional file 4).
Appearance of this form of MAVS was a consequence
of RLR activation (Additional file 4A) and treatment
with l phosphatase promoted its disappearance (Addi-
tional file 4B), confirming a phosphorylation of the lar-
ger MAVS isoform once stimulated by RLRs. Therefore,
this observation suggests that to be degraded, the higher
MAVS isoform is not only ubiquitinated but is also
phosphorylated, likely explaining why the overexpression
of TRIM25 only promotes limited degradation of endo-
genous MAVS (Figure 3D).
IRF3 phosphorylation depends on a translocation of a
signaling complex from mitochondria to cytosol upon
proteasomal degradation of MAVS
Since our data indicate that following RLR activation the
proteasome-mediated degradation of MAVS is required
for IRF3 activation, we explored how this degradation is
involved. Several proteins, such as TRAF3, NEMO and
TBK1, have been reported to be critical effectors down-
stream of MAVS to trigger IRF3 phosphorylation and
type I IFN production [1,11,17,18]. So we decided to
investigate whether the prevention of MAVS degrada-
tion perturbs their localization within cells. Hence, cells
were infected with SeV H4 in the presence or the
absence of a proteasome inhibitor, and at different time
points the presence of TRAF3, NEMO and TBK1 was
studied in cytosolic and mitochondrial fractions. TRAF3,
NEMO and TBK1 are cytosolic proteins, and their
respective amounts remained unaffected by the infection
in the presence or the absence of MG132 (Figure 5A).
Like IRF3, TBK1 and NEMO were not found associated
with purified mitochondria during infection, but inter-
estingly, when MAVS degradation was inhibited, some
TBK1 and NEMO were detected in the mitochondrial
fraction (Figure 5A). Since both proteins are cytosolic,
prevention of MAVS degradation likely promotes their
retention into the mitochondrial fraction. This was con-
firmed by immunofluorescence studies. Indeed, in con-
trol or SeV H4-infected cells, TBK1 was diffusely
localized in the cytosol, but when cells were pre-treated
with MG132, a significant redistribution of TBK1 to
mitochondria was observed in infected cells (Figure 5B).
This relocation was dependent of MAVS, since MAVS
knock down (Figure 1D) abrogated the association of
TBK1 with mitochondria after infection (Figure 5C) and
after cell fractionation, retention of both TBK1 and
NEMO in the mitochondrial fraction was not observed
(data not shown). A defect in the degradation of the lar-
ger MAVS isoform leads to a retention of both TBK1
and NEMO within the mitochondrial fraction and is
subsequently linked to an inhibition of IRF3 phosphory-
lation (Figure 5A). We, therefore, propose that following
RLR activation, MAVS allows the formation of a signal-
ing complex composed at least of NEMO and TBK1,
but this complex must be released into the cytosol con-
sequently to MAVS degradation for TBK1 to phosphor-
ylate IRF3 (Figure 6). Interaction between MAVS and
the signaling complex is likely indirect because, as pre-
viously reported [19], we did not detect any association
between MAVS and TBK1 or NEMO in co-immunopre-
cipitation experiments (unpublished observations). The
signaling complex may also contain the E3 ubiquitin
ligase TRAF3 because proteasome inhibition slightly
increased the proportion of TRAF3 associated with puri-
fied mitochondria once RLRs are activated (Figure 5A).
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Figure 4 Involvement of TRIM25 in the regulation of MAVS. (A) HeLa cells were transfected with empty or TRIM25-V5 vector and co-
transfected with an IFN-b promoter reporter as well as with renilla luciferase as an internal control. Twenty-four hours later, cells were
transfected or not with HMW Poly(I:C) (1 μg/ml). Luciferase assay was performed 8 hr after transfection and was normalized using renilla
luciferase activity. Data represent means ± SD (n = 3). (B) HeLa cells were transfected with control, MAVS, RIG-I and TRIM25 siRNAs for 48 hr,
next transfected with an IFN-b promoter reporter as well as with renilla luciferase as an internal control. Twenty-four hours later, cells were
transfected or not with Poly(I:C) (1 μg/ml). Luciferase assays were performed 8 hr after transfection and normalized using renilla luciferase
activity. Data represent means ± SD (n = 3). The knockdown efficiency of MDA-5 and RIG-I was evaluated by immunoblot. For the knockdown of
MAVS and TRIM25, see Figures 1D and 4E respectively. (C) Concentrations of mouse IFN-b in cellular supernatant from WT or TRIM25
-/- MEFs, 9
hr after transfection with 2 μg/ml of Poly(I: C). IFN-b concentrations were assessed by ELISA. Data represent means ± SD (n = 2). (D)
Concentrations of mouse IL-6 in cellular supernatant from WT or TRIM25
-/- MEFs, 9 hr after transfection with 2 μg/ml of Poly(I: C). IL-6
concentrations were assessed by ELISA. Data represent means ± SD (n = 2). (E) HeLa cells were transfected with control or TRIM25 siRNAs for 72
hr. Then, cells were transfected or not with Poly(I:C) (1 μg/ml), and 9 hr after transfection TRIM25, MAVS, p-IRF3, IRF3, p-IBa and IBa were
analyzed in cell extracts by immunoblotting. Actin was used as a protein loading control. Arrow indicates the phosphorylated state of MAVS.
Values represent the ratio of the larger MAVS isoform band normalized with respect to the loading control. (F) WT or TRIM25
-/- MEFs were
transfected or not with Poly(I:C) (2 μg/ml), and 10 hr after transfection TRIM25, MAVS, p-IRF3, IRF3, p-IBa and IBa were analyzed in cell
extracts by immunoblotting. Actin was used as a protein loading control. (F) WT or TRIM25
-/- MEFs were transfected or not with Poly(I:C) (2 μg/
ml) in the presence of MG132. Three hours later, MAVS and its ubiquitination were analyzed in mitochondrial extracts by immunoblotting with a
short and a long exposure respectively. VDAC was used as a protein loading control.
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impaired IRF3 phosphorylation following RLR activation
( F i g u r e5 A ) ,i td i dn o tp r e c l u d eI Ba phosphorylation
(Figure 5A) suggesting againt h a tM A V Sd e g r a d a t i o ni s
not required for NF-B signaling.
Discussion
Previous studies have shown that the mitochondrial
adaptor protein MAVS is essential to the RLR antiviral
innate immune response [1,3-5,20,21]. Nevertheless, the
function of MAVS, as well as its regulation in the RLR
signaling pathway, has remained unclear. Very recently,
it has been described that MAVS forms functional
prion-like aggregates after viral infection and that these
aggregates are required for the activation of IRF3 in the
cytoplasm [16].
MAVS is expressed as two major isoforms, and here we
demonstrate that RLR activation induces the specific pro-
teasome-mediated degradation of the larger MAVS iso-
form after its polyubiquination, but, importantly, this
degradation seems to be required for the downstream sig-
naling that leads to type I IFN but not pro-inflammatory
cytokines production. We identified the RING-finger E3
ubiquitin ligase TRIM25 as an E3 ubiquitin ligase that cat-
alyzes Lys 48-linked ubiquitination of MAVS, leading to
its degradation by the proteasome. TRIM25 has already
been shown to play a critical role in the RLR pathway
because it promotes Lys 63-linked ubiquitination of the
CARD domain of RIG-I, but not of the related helicase
MDA-5, to enhance and stabilize the interaction with the
CARD domain of MAVS [13]. Nevertheless, it was
reported that TRIM25 (also called Efp) targets the protea-
some-mediated degradation of 14-3-3 s and KLF5 [14,15]
confirming that TRIM25 is capable of triggering Lys 48-
linked ubiquitination as well. Hence, TRIM25 appears as
an E3 ubiquitin ligase with a crucial dual role in the posi-
tive regulation of the RLR pathway through its function on
RIG-I to favor the RIG-I/MAVS interaction as well as on
MAVS to promote its proteasome-mediated degradation,
which is likely required for IRF3 but not NF-B activation.
How MAVS is extracted from the mitochondrial outer
membrane before proteasome degradation is currently
unknown but it may involve the AAA ATPase cdc48/p97/
VCP, thought to extract integral membrane proteins from
the lipid bilayer and chaperone them to the proteasome,
as it is the case for Mcl-1 and Mitofusins [22].
A
B C
Figure 5 MAVS degradation is required to release into the cytosol a signaling complex involved in IRF3 activation. (A) HeLa cells were
infected with SeV H4 in the presence or the absence of MG132. At various times after infection, cytosolic fraction and mitochondrial fraction
were prepared. MAVS, TRAF3, p-IRF3, IRF3, p-IBa,I Ba NEMO and TBK1 were analyzed in each fraction by immunoblotting. Actin and VDAC
were used as a protein loading control for cytosol fraction and mitochondrial fraction, respectively. (B) HeLa cells were infected or not with SeV
H4 for 8 hr in the presence or the absence of MG132. Co-localization (yellow) of TBK1 (green) with mitochondria (red) was observed by
immunofluorescence. Line scans show the fluorescence intensities of TBK1 (green) and mitochondria (red) along the selected line. (C) Control or
MAVS siRNA were transfected into HeLa cells for 72 hr. Then, HeLa cells were infected or not with SeV H4 for 8 hr in the presence or the
absence of MG132. Co-localization (yellow) of TBK1 (green) with mitochondria (red) was observed by immunofluorescence. Line scans show the
fluorescence intensities of TBK1 (green) and mitochondria (red) along the selected line.
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larger MAVS isoform that is observed following RLR acti-
vation was prevented, but, surprisingly, an accumulation
of a phosphorylated even larger isoform of MAVS was
detected as well. So it seems that to promote its degrada-
tion by the proteasome, MAVS must undergo a phosphor-
ylation in addition to an ubiquitination, as is the case for
the NF-B inhibitor IBa [11]. The nature and function
of this phosphorylation, as well as the kinase(s) involved in
this process, deserve further investigations.
Once the specific degradation of the larger MAVS iso-
form was prevented with a proteasome inhibitor, a reten-
tion of NEMO and TBK1, two essential mediators in type
I IFN production, was observed in the mitochondrial frac-
tion. While this mitochondrial retention of both proteins
requires the presence of MAVS, we did not detect any
direct interactions between MAVS and either NEMO or
TBK1 (unpublished data), indicating an indirect associa-
tion probably through ubiquitin chains. Indeed, a study
has unveiled a key role of ubiquitin chains in IRF3 activa-
tion downstream of MAVS with NEMO functioning as a
sensor of Lys 63 polyubiquitin chains to activate TBK1
[19]. In this model, an important question that remains to
be resolved is the identity of the E3 ubiquitin ligase(s) that
synthetizes the Lys 63 ubiquitin chains to mediate IRF3
activation by MAVS. A candidate is TRAF3, because this
E3 ubiquitin ligase has been shown to be important for
type I IFN production by RLRs [18,23], but in our hands
the knock down of TRAF3 did not impair the activation of
the IFNb promoter (data not shown), suggesting that
other E3 ubiquitin ligases can compensate the loss of
TRAF3, as previously proposed [19]. Nevertheless, we
found that a small fraction of TRAF3 is associated with
mitochondria and this fraction was slightly increased
when MAVS degradation was inhibited, indicating that
TRAF3 may be a component of the signaling complex
downstream of MAVS and composed of at least NEMO
and TBK1.
Conclusions
At the mitochondrial surface, MAVS likely serves as a
recruitment platform for the assembly and activation of a
signaling complex involving NEMO and TBK1 and
required for IRF3 activation. Our observation that IRF3
was not phosphorylated and activated by TBK1 unless the
NEMO/TBK1 complex translocates from the mitochon-
dria into the cytosol after the proteasomal degradation of
MAVS suggests that the cytoplasmic translocation of the
Figure 6 IRF3 signaling depends on a translocation of signaling upon proteasomal-degradation of MAVS. In non-activated cells, MAVS is
associated to mitochondria through its C-terminal transmembrane domain. RLR activation induces MAVS oligomerization and aggregation [16]
(to simplify the model, only two MAVS molecules are shown as forming an aggregate), then MAVS recruits TRAF3 and other E3 ubiquitin ligases
which function to catalyze Lys 63-linked polyubiquitination of target proteins including TRAF3 itself. The Lys 63-linked polyubiquitin chains (in
green) recruit NEMO which in turn binds to TBK1 and TBK1 is activated. Concomitantly, TRIM25 induces Lys 48-linked polyubiquitination (in red)
of MAVS. The proteasomal degradation of MAVS results in the translocation of the MAVS-assembled complex into the cytosol where activated
TBK1 phosphorylates IRF3 to promote type I IFN production.
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Page 9 of 13MAVS-assembled signaling complex is required for an
optimal IRF3 activation (Figure 6).
Methods
Cell culture and viral infection
HEK293T cells, HeLa cells and MEFs were cultured in
standard conditions. TRIM25-/- MEFs were kindly pro-
vided by Dr. J.U. Jung (Department of Molecular Micro-
biology and Immunology, University of Southern
California, Los Angeles, CA, USA). Sendaï virus (SeV)
H4 and WT strains as well as infection protocol were
described previously [7,8], and the Multiplicity of infec-
tion (MOI) was 40.
Reagents
Proteasome inhibitors: MG132 (Calbiochem, Merck Che-
micals Ltd. Nottingham, UK)) and Lactacystin (Calbio-
chem) were used at 10 μMa n d2 5μM, respectively.
Proteases inhibitors: z-VAD-fmk (Calbiochem), qVD-fmk
(Calbiochem), Leupeptin Hemisulfate (mpbio, Santa Ana,
CA, USA) and Pepstatin A (Sigma-Aldrich, St. Louis, MO,
USA) were used at 50 μM. Staurosporine (Sigma) was
used at 2 μM. Interferons a and b (R&D Systems, Minnea-
polis, MN, USA) were used at 3,000 U/ml and 3,200 U/ml,
respectively. HMW Poly(I:C) (Invivogen, San Diego, CA,
USA) was transfected at 1 or 2 μg/ml. Lambda protein
phosphatase (l-PPase) was provided from New England
Biolabs (NEB, Ipswich, MA, USA) (P0753S). Neutralizing
anti-IFNAR1 (a gift of Dr. P. Eid) was used at 50 μg/ml.
Protein extraction and immunoblot analysis
Cells were lysed in buffer-A (20 mM Tris-HCl (pH 7.4),
137 mM NaCl, 2 mM EDTA, 1% Triton X-100, 2 mM
sodium pyrophosphate, 10% Glycerol, 25 mM b-glycero-
phosphate, 1 mM sodium orthovanadate) supplemented
w i t ht h ep r o t e a s ei n h i b i t o rm i x t u r eC o m p l e t e( R o c h e
Molecular Biochemicals, Meylan, France)). After incuba-
tion on ice for 20 minutes, a soluble extract was collected
after centrifugation at 11,000 g for 10 minutes at 4°C. The
lysate (20 μg) was boiled in SDS sample buffer and
resolved by SDS-polyacrilamide gel electrophoresis.
Immunoblot analysis was performed with specific antibo-
dies and the Ag-Ab complexes were visualized by chemi-
luminescence (Immobilon Western, Merck Millipore,
Billerica, MA, USA). For total cell extracts, cell were lysed
in buffer-A supplemented with 3% SDS.
Antibodies
The primary antibodies used in immunoblotting were as
follows: mouse monoclonal anti-RIG-I (Alexis Biochem-
icals, San Diego, CA, USA, clone Alme-1{) (1:2,000 dilu-
tion), mouse monoclonal anti-Cardif/MAVS (Alexis
Biochemicals, clone Adri-1) (1:4,000), rabbit polyclonal
anti-rodent MAVS (Cell Signaling Technology, Danvers,
MA, USA) (1:4,000), mouse monoclonal anti-actin
(Sigma-Aldrich, St. Louis, MO, USA, clone AC-40)
(1:5,000), rabbit polyclonal anti-MDA-5 (Alexis Biochem-
icals) (1:2,000), rabbit monoclonal anti-phospho-IRF3
(Cell Signaling Technology, clone 4D4G) (1:1,000), rabbit
polyclonal anti-IRF3 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) (1:1,000), rabbit monoclonal anti-IRF3
(Cell Signaling Technology) (1:2,000), mouse monoclonal
anti-phospho-IBa (Cell Signaling Technology, clone
5A5) (1:2,000), rabbit polyclonal anti-IBa (Santa Cruz
Biotechnology, C-21) (1:2,000), mouse monoclonal anti-
IKKι/IKKε/TBK1 (Imgenex, San Diego, CA, USA, clone
72B587) (1:1,000), mouse monoclonal anti-PARP (BD,
Franklin Lakes, NJ, USA, clone C2-10) (1:4,000), rabbit
polyclonal anti-Stat1 (Upstate Biotechnology, Merck Milli-
pore, Billerica, MA, USA) (1:1,000), rabbit polyclonal anti-
phospho-Stat1 (Cell Signaling Technology, clone Tyr701)
(1:1,000), rabbit polyclonal anti-TRAF3 (Santa Cruz Bio-
technology, H-122) (1:500), mouse monoclonal anti-
VDAC (Calbiochem, clone 89-173/025) (1:4,000), rabbit
polyclonal anti-V5 (Sigma-Aldrich) (1:5,000), mouse
monoclonal anti-HA (Sigma-Aldrich) (1:5,000). The anti-
body used in immunoprecipitation of endogenous MAVS
was rabbit polyclonal anti-Cardif/MAVS (Alexis Biochem-
icals, clone AT107) and rabbit polyclonal anti-Myc
(Sigma-Aldrich) for the immunoprecipitation of Myc-
MAVS. The primary antibodies used for immunofluores-
cence microscopy were rabbit polyclonal anti-IRF3 (Santa
Cruz Biotechnology) (1:500), polyclonal anti-TOM20
(Santa Cruz Biotechnology) (1:800) and mouse monoclo-
nal anti-TBK1 (ProSci Incorporated, Poway, CA, USA,
Clone 108A429) (1:400).
Transfections and plasmids
Transfection of HEK293T cells was performed using the
calcium phosphate precipitation method. Transfection of
HeLa cells by DNA and poly(I:C) was performed using
Lipofectamine 2000 (Invitrogen, Life Technologies, Grand
Island, NY, USA {) and Oligofectamine (Invitrogen) was
used for transfecting siRNAs. The plasmid for the expres-
sion of TRIM25-V5 was provided by Dr. J.U. Jung.
Luciferase assays
Cells were plated in 24-well plates. On the second day,
cells were co-transfected with 50 ng of firefly luciferase
constructs under the control of the IFN-b promoter or
driven by three copies of an NF-B enhancer, and 10 ng
of the renilla luciferase pRL-TK plasmid (Promega). The
next day, cells were either infected by SeV or transfected
with poly(I:C) for a few hours. Transfected cells were
collected and luciferase activity was assessed using the
Dual-luciferase reporter assay (Promega) on a Fluorostar
Optima (BMG Labtech, Ortenberg, Germany). Each
experiment was carried out in triplicates. For each
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Page 10 of 13sample, to obtain relative fluorescence units (RLU), fire-
fly luciferase fluorescence units were normalized to
renilla luciferase fluorescence units.
Immunoprecipitation
Cell lysates were prepared in lysis buffer-B (50 mM Tris-
HCl (pH 7.5), 140 mM NaCl, 5 mM EDTA, 5% glycerol,
1% Triton X-100, and 1% Nonidet P-40) supplemented
with the protease inhibitor mixture Complete, on ice for
20 minutes. Soluble proteins (500 μg) were subjected to
immunoprecipitation with an anti-MAVS (2.5 μg/ml), or
rabbit anti-IgG antibody as a control or an anti-Myc anti-
body. An aliquot of the total lysates was included as a con-
trol. After one hour, 20 μl of equilibrated protein
G-magnetic beads (Ademtech SA, Pessac, France) was
added. Immunoprecipitation was carried out for one hour.
The beads were then washed three times with buffer-B.
Immune complexes were resolved by SDS-PAGE and
immunoblotted.
Lambda phosphatase test
Following immunoprecipitation, the G-magnetic beads
were washed twice with the lysis buffer-B, and then twice
with the lysis buffer B without EDTA and without the pro-
tease inhibitor mixture. Then, each sample was incubated
with the reaction mixture (2.5 μl of reaction buffer pro-
vided with the l Phosphatase kit (NEB), 2.5 μlM n C l 2
(provided with the kit), 10 μl lysis buffer-B without
EDTA/inhibitors and 10 μl l-Phosphatase (NEB) or lysis
buffer-B only for control) for 30 minutes at 30°C. Finally,
Immunoblot and phosphorylation of MAVS were resolved
by SDS-PAGE.
Immunofluorescence microscopy
Cells grown in LabTek (Fisher Scientific, Illkirch, France)
chambers were fixed for 10 minutes in 4% paraformalde-
hyde, followed by permeabilization with 0.15% Triton
X-100 in PBS for 15 minutes. The cells were then incu-
bated for one hour in blocking buffer (2% BSA in PBS) fol-
lowed by incubation overnight with primary antibodies.
Next, cells were washed three times for 10 minutes each
in PBS, then incubated for 1 hr with Alexa Fluor second-
ary antibodies. Images were acquired using a Leica SP6
confocal microscope (Leica Microsystems, Wetzlar, Ger-
many) through a 63x oil fluorescence objective.
Signal intensities from each channel were recon-
structed by plotting pixel values of each channel along
lines drawn through optical sections. Multichannel
images were separated into single channels and exported
to the ImageJ software (National Institute of Health,
Bethesda, MD, USA). Measurements of the pixel intensi-
ties were made along the lines shown in the respective
picture.
Enzyme-Linked Immunosorbent Assays (ELISA)
MEFs were plated in 24-well plates at a cell density of
2.10
5 cells per well. Eight hours later, cells were infected
with SeV or transfected with poly(I:C). Supernatants of
cells were collected and ELISA assay was performed fol-
lowing the manufacter’s protocol (PBL Biomedical
Laboratories, Piscataway Township, NJ, USA, Mouse
Interferon Beta ELISA Kit v.1.4 and R&D Systems,
Mouse IL-6 immunoassay).
Small interfering RNA (siRNA)
For down-regulation of proteins, siRNA oligos directed
against MAVS, TRIM25, RIG-I and MDA-5 at a final
concentration of 20 nM were transfected into cells for
72 hr. For HeLa cells, oligofectamine was used accord-
ing to the manufacturer’s instructions whereas for
HEK293T cells, siRNA transfection was performed using
the calcium phosphate precipitation method. siRNAs
were purchased from Ambion (Life Technologies, Grand
Island, NY, US). The sequence of the siRNA oligos is as
follows (only sense strands are shown):
MAVS siRNA1: CCGUUUGCUGAAGACAAGAtt
MAVS siRNA2: CCACCUUGAUGCCUGUGAAtt
TRIM25 siRNAa: CCAUAGACCUCAAAAACGAtt
TRIM25 siRNAb: CAACAAGAAUACACGGAAAtt
RIG-I siRNA: GGAAGAGGUGCAGUAUAUUtt
MDA-5 siRNA: GUUCAGGAGUUAUCGAACAtt
Mass spectrometry
After SeV H4 infection for four hours, a purified MAVS
complex was analyzed by means of one-dimensional gel
electrophoresis in combination with the nano liquid-
chromatography tandem using 10 segment GelC/MS
and spectral counting by mass spectrometry. Mass spec-
trometry was performed by Nextgensciences (Ann
Arbor, MI, USA).
Cellular fractionation
Isolation of mitochondrial and cytosolic fraction: HeLa
cells were harvested in isotonic buffer-C (210 mM manni-
tol, 70 mM sucrose, 1 mM EDTA and 10 mM HEPES (pH
7.5)), supplemented with the protease inhibitor mixture
Complete (Roche Molecular Biochemicals). Cells were
broken by 15 passages through a2 5 - g a u g en e e d l ef i t t e d
onto a 5 ml syringe, and the suspension was then centri-
fuged at 2,000 g at 4°C for 5 minutes to remove nuclei and
unbroken cells. This procedure was repeated until nearly
all of the cells were broken. Heavy membrane fractions
enriched in mitochondria were obtained by centrifugation
at 10,000 g at 4°C for 10 minutes, and supernatant was
centrifuged at 25,000 g for 30 minutes and supernatant
was kept as the “cytosolic fraction”. The heavy membrane
fraction was resuspended in buffer-C and layered on top
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sucrose in 10 mM Hepes (pH 7.5), 1 mM EDTA, and 0.1%
BSA on top of 1.6 M sucrose in 10 mM Hepes, (pH 7.5), 1
mM EDTA, and 0.1% BSA. Then, samples are centrifuged
at 30,000 g for 2 hr at 4°C. Mitochondria are recovered at
the 1.6 to 1.2 M sucrose interface, washed in buffer C and
centrifuged at 13,000 g at 4°C for 10 minutes, and resus-
pended in buffer C. The mitochondrial pellet was lysed
and used for immunoblot analyses.
Densitometric image analysis
To measure the relative expression level of proteins in
cell extracts, acquired images were densitometrically
analyzed by using the ImageJ software.
Statistical analyses
Data were compared using Student’s t-test. Differences
were considered to be significant if P < 0.05. ***P <
0.001, **0.001 <P < 0.01, *0.01 <P < 0.05. NS, not
significant.
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Additional material
Additional file 1: Figure S1. Analysis of MAVS by immunoblotting in
the absence or the presence of SDS. HEK293T or HeLa cells were
infected or not with SeV H4 for 10 hrs. Next, cells were lysed in lysis
buffer supplemented or not with 3% SDS. MAVS was analyzed in cell
extract by immunoblotting. Actin was used as a protein loading control.
Additional file 2: Figure S2. Degradation of the larger MAVS isoform is
independent of type I IFNs. (A) HEK293T cells were treated with IFN a2
or b for 8 and 16 hr. After treatment, RIG-I, MAVS, p-Stat1 and Stat1 were
analyzed in cell extracts by immunoblotting. Tubulin was used as a
protein loading control. (B) HEK293T cells were infected with SeV H4 or
treated with IFN a2 for 8 hr. RIG-I, MAVS, p-Stat1, Stat1, p-IRF3 and IRF3
were analyzed in cell extracts by immunoblotting. Tubulin was used as a
protein loading control. (C) HEK293T cells were infected or not with SeV
H4 for 10 hr in the presence or the absence of a neutralizing antibody
raised against IFNAR1 (50 μg/ml). Next MAVS, p-Stat1 and Stat1 were
analyzed in cell extracts by immunoblotting. Tubulin was used as a
protein loading control.
Additional file 3: Figure S3. Degradation of the larger MAVS isoform is
independent of specific proteases. (A) HeLa cells were infected with SeV
H4 or treated by staurosporine in the presence or the absence of the
caspase inhibitor zVAD-fmk. Next, at various times, MAVS and PARP were
analyzed by immunoblotting. Actin was used as a protein loading
control. (B) HEK293T cells were transfected either with an IFN-b
promoter reporter or with NF-B reporter as well as with renilla luciferase
as an internal control. Twenty hours after transfection, cells were infected
with SeV WT or SeV H4 or else left non-infected and treated with
caspase inhibitors. Luciferase assays were performed 8 hr after infection
and was normalized using renilla luciferase activity. The error bars
represent standard deviation from the mean value obtained from
triplicate experiments. (C) HEK293T cells were infected with SeV H4 and
treated with proteases inhibitors, and at various times after infection RIG-
I, MAVS, p-IRF3, IRF3, p-IBa and IBa were analyzed in cell extracts by
immunoblotting. Actin was used as a protein loading control. (D)
HEK293T cells were transfected either with an IFN-b promoter reporter or
with NF-B reporter as well as with renilla luciferase as an internal
control. Twenty hours after transfection, cells were infected with SeV WT
or SeV H4 or else left non-infected and treated with leupeptin and
pepstatin. Luciferase assays were performed 8 hr after infection and were
normalized using renilla luciferase activity. Data represent means ± SD (n
= 3).
Additional file 4: Figure S4. MAVS is phosphorylated after RLR
activation. (A) HeLa cells were infected with SeV H4. At various times
after infection, MAVS was analyzed by immunoblotting. (B) HeLa cells
were infected with SeV H4 for six hours. Next, endogenous MAVS was
immunoprecipitated from cell extracts with a specific antibody. Following
immunoprecipitation, samples were treated or not with l phosphatase
for 30 minutes. The presence of MAVS and its phosphorylation was
examined by immunoblotting. Arrows indicate the phosphorylation of
MAVS.
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